BioCryst Pharmaceuticals | BCRX - L'Utile Ante Imposte





L'Utile Ante Imposte Cambiamento Data
Alnylam Pharmaceuticals USD 221.65M 60.52M 2026-03
BioCryst Pharmaceuticals USD 248.02M 235.89M 2025-12
Chugai Pharma JPY 169.02B 8.83B 2026-06
Daiichi Sankyo JPY 106.73B 48.96B 2025-12
DBV Technologies USD -47.4M 14.24M 2026-03
Enanta Pharmaceuticals USD -22.71M 95.08M 2024-12
Gilead Sciences USD 2.08B 1.56B 2025-12
GlaxoSmithKline GBP 2.14B 919M 2026-03
Glaxosmithkline GBP 2.14B 312M 2026-03
Incyte USD 343.6M 46.34M 2026-03
Ionis Pharmaceuticals USD -93M 135M 2026-03
Karyopharm Therapeutics USD -39.9M 9.01M 2025-12
Neurocrine Biosciences USD 246.8M 7.4M 2026-03
Novavax USD 17.9M 220.94M 2025-12
PTC Therapeutics USD -2.46M 136.62M 2026-03
Regeneron Pharmaceuticals USD 1.04B 719.6M 2025-12
Roche Holding CHF 11.17B 6.38B 2026-06
Sarepta Therapeutics USD 343.17M 750.85M 2026-03
Ultragenyx Pharmaceutical USD -184M 56M 2026-03
Vertex Pharmaceuticals USD 1.25B 78.1M 2026-03